Barclays PLC Has $1.32 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Barclays PLC raised its position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 103.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,449 shares of the company's stock after buying an additional 84,118 shares during the quarter. Barclays PLC owned 0.18% of Scholar Rock worth $1,324,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Scholar Rock by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock valued at $25,000 after acquiring an additional 514 shares in the last quarter. Quarry LP boosted its holdings in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company's stock valued at $36,000 after purchasing an additional 4,373 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Scholar Rock during the 2nd quarter worth approximately $98,000. Hsbc Holdings PLC acquired a new position in shares of Scholar Rock during the 2nd quarter worth approximately $100,000. Finally, Point72 DIFC Ltd bought a new position in shares of Scholar Rock during the second quarter worth approximately $103,000. Institutional investors own 91.08% of the company's stock.

Insider Activity at Scholar Rock

In other news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total value of $15,759,076.17. Following the transaction, the insider now owns 10,850,005 shares in the company, valued at approximately $417,616,692.45. The trade was a 3.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Edward H. Myles sold 206,240 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the sale, the chief financial officer now owns 161,088 shares of the company's stock, valued at approximately $4,278,497.28. This trade represents a 56.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,821,386 shares of company stock worth $56,395,016 in the last quarter. 19.20% of the stock is owned by insiders.

Scholar Rock Trading Down 2.8 %

Shares of SRRK stock traded down $1.27 during mid-day trading on Friday, reaching $44.46. 463,838 shares of the stock traded hands, compared to its average volume of 1,137,612. The company has a market cap of $4.16 billion, a price-to-earnings ratio of -18.92 and a beta of 0.58. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock's fifty day simple moving average is $35.25 and its two-hundred day simple moving average is $19.39. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.19.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SRRK. HC Wainwright increased their price target on Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Truist Financial upped their target price on Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, November 25th. Piper Sandler raised their price target on Scholar Rock from $28.00 to $42.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 15th. JPMorgan Chase & Co. upped their price objective on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a research report on Monday, October 14th. Finally, Wedbush raised their target price on shares of Scholar Rock from $40.00 to $47.00 and gave the company an "outperform" rating in a report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $40.43.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.